Skip to content
★ Sign in to follow
Hypera S/A logo

Hypera S/A Stock: price and insider trades · Brazil

BR·Mcap R$18.9BHealth Care

Hypera S/A: what insiders have been doing

Hypera S/A, founded in 2001, is a Health Care company based in São Paulo, Brazil. Its directors and officers file their transactions with CVM (Brazil). Between 23 October 2025 and 23 October 2026, 4 insiders published 193 filings.

Both sides are active: 72 purchases worth €134.3M and 62 sales worth €3.5M, from 2 insiders and 2 insiders respectively. The totals exclude 28 filings filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The filings include the largest purchase, €30.0M, on 10 June 2026, which represents 1.2% of the company's market value. On the buying side, the filings list 1 major shareholder and 1 senior executive among the declarants.

The latest purchase is recent: it was published 30 days ago, on 9 October 2026. Between a trade and the moment it shows up on CVM (Brazil), the median delay is 23 days. This delay matters because a trade only becomes useful information once it is public.

Across the 343 companies tracked on its exchange, the median is 23 filings; at 193 filings, this issuer sits above that mark. The full history, which starts in 2019, counts 184 purchases against 329 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by CVM (Brazil) and describes the past, not future prices; it is not investment advice.

Insider Decl.
1,155
Thresholds
n/a
Buy Volume
€135M
184 ops. · all time
Sell Volume
€26M
329 ops. · all time

Who traded when

BuySale
Anonymous (Diretor ou Vinculado)25 buys100 sales
Anonymous (Controlador ou Vinculado)57 buys1 sale
Anonymous (Conselho de Administração ou Vinculado)6 buys6 sales

Analyst consensus: bullish or bearish?

Analysts rate Hypera S/A Strong Buy (bullish), based on 15 analysts. Average price target: R$31.02.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 5,228 of 26,897 companies
67.4
score / 100
Value
70
Quality
65
FCF yld11%
Earn yld7.7%
EV/EBITDA11.0x
ROE13%
Gross mgn59%
Net mgn16%
Debt/EBITDA4.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

R$26.81
Analyst consensus
15 analysts
Strong buy
R$24.00Target R$31.02(+16%)R$36.00
Income statement
RevenueR$7.7B
Gross profitR$4.5B59% margin
EBITDAR$2.3B29% margin
Net incomeR$1.2B19.8% margin
Valuation
PER (trailing)10.0x
PER (forward)8.6x
P/Book1.3x
Beta0.07
Balance sheet & cash
Market capR$18.9B
Total debtR$9.3B
Free Cash FlowR$1.8B
Debt / Equity53%
Profitability & ownership
ROE13.2%
ROA6.3%
% insiders56.6%
% institutions29.7%
Last declaration on 9 October 2026
Declarations1,155 total

25 of 1155 declarations

About Hypera S/A

Hypera S/A is a Brazilian company specializing in the pharmaceutical sector. It is listed on the São Paulo Stock Exchange, BVMF.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations